Table 1

Patient characteristics in the gefitinib and erlotinib groups
Characteristics Gefitinib (n = 232) Erlotinib (n = 86) p value
Median age (Range) 67 (24–90) 66 (34–90) 0.36
< 70 139 57
≥ 70 93 29
Gender 0.90
Male 105 38
Female 127 48
Histology 0.32
Adenocarcinoma 223 80
Squamous cell carcinoma 8 5
Other 1 1
Smoking status 0.38
Ever smoker 130 43
Never smoker 102 43
ECOG performance status 0.001
0 30 11
1 143 68
≥ 2 59 7
EGFR mutation status < 0.001
Positive 91 53
Negative 4 22
Unknown 137 11
Stage 0.75
≤ IIIB 48 16
IV 184 70
CYP2D6 activity 0.42
functional 156 64
reduced 50 16
unknown 26 6
HBs antigen 1.00
Positive 2 0
Negative 211 85
Unknown 2 1
HCV antibody 0.10
Positive 15 5
Negative 200 80
Unknown 17 1
Pretreatment LFT 0.42
normal 155 62
abnormal 77 24

*Fisher’s exact test were applied to compare patient characteristics.

ECOG, Eastern Cooperative Oncology Group; EGFR, Epidermal Growth Factor Receptor; HCV, hepatitis C virus; HBs, hepatitis B surface; LFT, liver function test; CYP2D6, cytochrome P450 2D6.

Suzumura et al.

Suzumura et al. BMC Cancer 2012 12:568   doi:10.1186/1471-2407-12-568

Open Data